secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001193805-24-000893
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic appoints Jason Tardio as COO/President and promotes Werner Gladdines to CDO
--------------------------------------------------------------------------------

- Jason Tardio, former Novartis MS franchise head and Biogen exec, appointed COO and President effective July 12, 2024.
- Tardio will lead launch preparedness for vidofludimus calcium (IMU-838) and partnership efforts.
- Compensation: $500,000 base salary, up to 40% bonus, $120,000 signing bonus, and 500,000 stock options with 4-year vest.
- Werner Gladdines promoted from VP to Chief Development Officer, overseeing clinical operations.
- Phase 2 CALLIPER trial in progressive MS readout expected April 2025; phase 3 ENSURE trials in relapsing MS due 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524000893/0001193805-24-000893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524000893/e663765_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-000893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer